Zevra Therapeutics, Inc.

NASDAQ:ZVRA

Biotechnology

Healthcare
$9.40 +2.44%

+$0.31 today

Market cap
$559.34M
Beta
0.89
P/E (TTM)
6.1
EPS (TTM)
$2.13
52W Low $7.16High $14.27

Volume 0.84M

Average 1.43M

Big Five Numbers

Zevra Therapeutics, Inc. growth analysis

Start with the long-run numbers that show whether ZVRA compounds: return on capital and growth in sales, earnings, equity, and free cash flow.

Big Five Numbers

CAGR by period · ROIC shows average

Metric 10yr 5yr3yr1yr
EPS
N/AN/AN/AN/A
Revenue
N/AN/A+118.8%+350.9%
Equity
N/AN/A+8.7%+226.0%
Cash
N/AN/A-1.6%+84.7%
ROIC
N/A-26.3%-32.7%-1.7%

Analysis

Latest growth is strongest in Revenue at +350.9% and weakest in ROIC at -1.7%. Three-year average ROIC is -32.7%, which helps show whether that growth is being earned efficiently.

Growth analysis

Is growth accelerating or fading?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
+10.0% (5yr)4 analysts
RevenueN/AN/A+118.8%
+22.4% (5yr)5 analysts
Net IncomeN/AN/AN/A
+8.4% (5yr)5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Recent growth has been strongest in Revenue at +118.8% over three years. Forward estimates point to Revenue at +22.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Revenue segments

Where does the growth come from?

Break revenue down by product and geography to see which parts of the business drive the trend.

Revenue by segment

Where ZVRA earns its revenue, as reported in company filings

  • License
Revenue by segment for FY2023
Segment · FY2023 Revenue Share YoY
License$18M100.0%—

Figures in USD. Segments account for 65.5% of reported FY2023 revenue; $9.46M is not attributed to a segment.

Free cash flow

Does growth turn into cash?

Check whether reported growth converts into free cash flow after capital spending.

Free Cash Flow

Net Income to FCF bridge

Cash Flow Statement

FY2025

= Net Income$83.2M
+ D&A$4.1M
+ Stock-Based Comp$12.6M
+ Deferred Tax$3.4M
- Working Capital-$26.5M
- Other Non-Cash-$78.5M
= Operating Cash Flow-$1.6M
- Capex-$835.0K
= Free Cash Flow-$2.4M

Analysis

FY2025 free cash flow is -$2.4M. FCF conversion is -2.9% of net income. Operating cash flow was -$1.6M, with capex of -$835.0K. The largest bridge item is Other Non-Cash at -$78.5M.

Price targets

What do analysts expect from the price?

Compare the current price with the low, average, and high analyst targets.

Wall Street price targets

1-year price history with analyst consensus target

Growth

Unlock analyst target range

Sign in free to see low, average, high targets and implied upside for ZVRA.

Sign in free

Analyst ratings

How do analysts rate the stock?

Review the buy, hold, and sell split and recent upgrades and downgrades.

Analyst ratings

Buy, hold, and sell recommendations and recent rating changes

Unlock analyst ratings

Sign in free to see the buy/hold/sell breakdown and recent rating changes for ZVRA.

Sign in free

Competitor growth

How does Zevra Therapeutics, Inc. grow against peers?

Compare historical and forecast growth with similar companies.

Competitor Growth

Peer CAGR comparison & forward estimates

CompanyMarket Cap10yr5yr3yrFwd

Neurocrine Biosciences, Inc.

NBIX

$16.94B+64.5%+22.3%+24.3%
+13.9% (5yr)10 analysts

Jazz Pharmaceuticals plc

JAZZ

$15.50B+12.4%+12.5%+5.3%
+8.0% (5yr)15 analysts

Praxis Precision Medicines, Inc.

PRAX

$9.17B———
—9 analysts

Alkermes plc

ALKS

$7.90B+8.9%+7.3%+9.9%
+12.0% (5yr)7 analysts

Xenon Pharmaceuticals Inc.

XENE

$3.98B-7.0%-25.3%-7.4%
+166.4% (5yr)5 analysts

Supernus, Inc.

SUPN

$1.73B+17.4%+6.7%+2.5%
+32.9% (5yr)1 analysts

GH Research PLC

GHRS

$1.31B———
—6 analysts

Alto Neuroscience, Inc.

ANRO

$1.18B———
—6 analysts

MapLight Therapeutics, Inc.

MPLT

$308.98M———
—4 analysts

Neumora Therapeutics, Inc. Common Stock

NMRA

$80.59M———
—7 analysts

Questions

Growth questions

Common questions about ZVRA's growth, answered from reported and forecast figures.

Is ZVRA growing revenue?

Revenue grew 350.9% year over year, from $23.61M to $106.47M.

Is ZVRA turning growth into profit?

The latest net margin is 78.2%, which shows how much revenue became net income.